-
Neuroligin 1 Loss Drives Striatal PKC Overactivation in ASD
2026-05-13
This study reveals that Neuroligin 1 deficiency in striatal D2 receptor-expressing neurons leads to hyperactivation of protein kinase C (PKC), driving excessive repetitive behaviors in a mouse model of autism spectrum disorder. Single-nucleus RNA sequencing and neuronal activity assays uncover new mechanistic links, highlighting PKC as a candidate target for intervention.
-
SP2509: Unlocking Precision Epigenetic Modulation in AML
2026-05-13
This thought-leadership article examines how SP2509—a highly selective Lysine-specific demethylase 1 antagonist—redefines acute myeloid leukemia (AML) research. It integrates mechanistic insight, translational strategy, and competitive positioning, while delivering actionable guidance for researchers navigating the rapidly evolving landscape of cancer epigenetics.
-
FGFR Inhibition and Multidrug Resistance: Insights from BGJ
2026-05-12
Boichuk et al. reveal that infigratinib (BGJ 398), a pan-FGFR inhibitor, can directly impair ABCB1-mediated drug efflux and resensitize multidrug-resistant tumor cells to chemotherapeutics. Notably, the study highlights that the selective FGFR1/VEGFR2 inhibitor PD 173074 does not share this ABCB1-modulatory effect, clarifying its mechanistic profile for oncology researchers.
-
Sulfo-NHS-LC-Biotin: Practical Guide for Protein Biotinylati
2026-05-12
Sulfo-NHS-LC-Biotin provides a water-soluble, membrane-impermeable solution for covalent labeling of primary amines, enabling selective biotinylation of extracellular or cell surface proteins. This reagent is unsuitable for reversible labeling or intracellular protein modification, making it best for protocols targeting accessible amines in aqueous environments.
-
Alternariol Drives Hepatic Stellate Cell Activation and Fibr
2026-05-11
This paper provides the first lncRNA-mRNA omics-based evidence that Alternariol (AOH), a major Alternaria mycotoxin, drives the transdifferentiation of human hepatic stellate cells into myofibroblasts—a central event in liver fibrosis. The findings clarify the molecular mechanisms of AOH-induced hepatotoxicity and introduce a novel detoxification strategy using CotA laccase, with major implications for food safety and liver disease research.
-
ML133 HCl: Selective Kir2.1 Potassium Channel Inhibitor Prof
2026-05-11
ML133 HCl is a highly selective potassium channel inhibitor targeting Kir2.1 channels, enabling precise studies in pulmonary artery smooth muscle cell proliferation research. Its potency, selectivity, and validated applications make it a reference tool for cardiovascular ion channel research.
-
Fluorescein Tyramide: Enhancing Sensitivity in Cell-Based As
2026-05-10
This article provides an in-depth, scenario-driven analysis of Fluorescein Tyramide (SKU K1084), guiding biomedical researchers and lab technicians through real-world assay challenges. Emphasizing protocol optimization, data reproducibility, and vendor reliability, it demonstrates how APExBIO's Fluorescein Tyramide outperforms conventional fluorescent labeling dyes for signal amplification in immunohistochemistry, in situ hybridization, and flow cytometry.
-
Nitrocefin: Chromogenic Cephalosporin Substrate for β-Lactam
2026-05-09
Nitrocefin offers rapid, sensitive colorimetric detection of β-lactamase activity, setting a new standard for antibiotic resistance research and inhibitor screening. Its robust colorimetric shift and compatibility with multiple assay formats make it a cornerstone for microbiological and clinical workflows.
-
MK-0812: Advancing Monocyte Trafficking Research in MASH Mod
2026-05-08
Explore how MK-0812, a potent CCR2 antagonist, uniquely enables precise dissection of monocyte trafficking and MCP-1 signaling in metabolic dysfunction-associated steatohepatitis (MASH) research. Gain deep scientific insights into its mechanism, evidence base, and optimal protocol considerations.
-
Eltanexor (KPT-8602): Precision Targeting of XPO1 in Cancer
2026-05-08
Discover how Eltanexor (KPT-8602), a potent XPO1 inhibitor, enables precision cancer research through unique modulation of nuclear export and the Wnt/β-catenin pathway. This comprehensive analysis explores its mechanistic depth, translational implications, and advanced assay considerations.
-
Optimizing O-GlcNAcylation Assays: Thiamet G (SKU B2048) in
2026-05-07
This in-depth guide addresses prevalent laboratory challenges in O-GlcNAcylation, cell viability, and bone differentiation assays. Leveraging validated data, it demonstrates how Thiamet G (SKU B2048) from APExBIO offers reproducible, high-sensitivity O-GlcNAcase inhibition, empowering robust experimental design for researchers studying neurodegeneration, bone biology, and leukemia.
-
Direct Reprogramming of Astrocytes to Motoneuron-like Cells
2026-05-07
The referenced study demonstrates that a defined combination of four transcription factors—ASCL1, MYT1L, POU3F2, and ISL1—can reprogram rat and human astrocytes into motoneuron-like cells. This approach provides a promising avenue for regenerative medicine research by enabling targeted neuronal replacement strategies for spinal cord injury.
-
SR-202 (PPAR antagonist): Reliable Tools for Metabolic and I
2026-05-06
This scientific guide explores real-world challenges in cell-based assays and demonstrates how SR-202 (PPAR antagonist, SKU B6929) offers reproducible, literature-backed solutions in insulin resistance, obesity, and macrophage polarization research. Bench scientists will find actionable, scenario-driven answers and validated protocol insights, all grounded in current data and supported by the APExBIO product dossier.
-
Homoharringtonine Rapidly Clears SARS-CoV-2 in URT Models
2026-05-06
This study demonstrates that homoharringtonine, a cytotoxic alkaloid, effectively inhibits SARS-CoV-2 replication and rapidly clears the virus from the upper respiratory tract in both animal models and human patients. The evidence positions homoharringtonine as a promising first-line antiviral intervention for future coronavirus epidemics.
-
CHI3L1-IN-5 (Compound Z17): Dual-Action Innovation in Neurod
2026-05-05
Explore CHI3L1-IN-5 (Compound Z17), a selective CHI3L1 inhibitor with a unique dual mechanism, advanced CNS penetration, and optimized pharmacokinetics. This article provides a rigorous, application-focused analysis that extends beyond protocol basics to help researchers unlock new strategies in neuroinflammation and Alzheimer's disease models.